This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ono-Merus Bispecific Antibody

Ono Pharmaceutical Company, Ltd.

Drug Names(s): Merus-Ono Bispecific Antibody

Description: Merus and Ono are co-developing an autoimmune bispecific antibody, utilizing Merus' bispecific antibodies, Biclonics, that have a full-length IgG format.

Deal Structure: Merus and Ono
In April 2014, Merus and Ono executed a research and license agreement to jointly develop bispecific antibody therapies in autoimmune diseases. In April 2015, Merus received a milestone payment for achieving preclinical proof-of-concept with a lead bispecific antibody. In October 2016, Merus announced that Ono and Merus have also extended their collaboration by signing an additional agreement for CMC activities to be carried out by Merus.

Partners: Merus B.V.


Ono-Merus Bispecific Antibody News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug